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Purpose: The influence of alendronate (ALN) treatment on the quantitative ultrasound 
  parameters of the calcaneus remains to be established in Japanese patients. The aim of the 
present clinical practice-based observational study was to examine the influence of ALN 
  treatment for 1 year on the speed of sound (SOS) of the calcaneus and bone turnover markers 
in postmenopausal Japanese women with osteoporosis.
Patients and methods: Forty-five postmenopausal Japanese women with osteoporosis who 
had received treatment with ALN for more than 1 year were enrolled in the study. The SOS 
and bone turnover markers were monitored over 1 year of ALN treatment.
Results: The urinary levels of cross-linked N-terminal telopeptides of type I collagen and 
serum levels of alkaline phosphatase decreased significantly from the baseline values (−44.9% 
at 3 months and −22.2% at 12 months, respectively). The SOS increased modestly, but 
  significantly, from the baseline value (0.6% at both 6 and 12 months). The percentage decrease 
in the urinary levels of cross-linked N-terminal telopeptides of type I collagen at 3 months was 
significantly correlated with the percentage increase in the SOS only at 6 months (correlation 
coefficient, 0.299).
Conclusion: The present study confirmed that ALN treatment suppressed bone turnover, pro-
ducing a clinically significant increase in the SOS of the calcaneus in postmenopausal Japanese 
women with osteoporosis.
Keywords: postmenopausal osteoporosis, quantitative ultrasound (QUS), SOS, bone turnover, 
biochemical markers
Introduction
Osteoporosis most commonly affects postmenopausal women, placing them at 
  significant risk for sustaining fractures. Alendronate (ALN) is widely used as a first-
line drug for the treatment of postmenopausal osteoporosis because of its established 
efficacy, according to the Fracture Intervention Trial and a recent systematic review 
of eleven randomized controlled trials (RCTs), against vertebral, nonvertebral, hip, 
and wrist fractures.1–3
Because ALN treatment increases bone mineral density (BMD) at the lumbar spine, 
femoral neck, and total hip in postmenopausal women with osteoporosis – as reported in 
the aforementioned Fracture Intervention Trial1,2 – the BMD measured by dual-energy 
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X-ray absorptiometry (DXA) remains the optimal method 
for monitoring the response to ALN treatment. Quantitative 
ultrasound (QUS) is a more recently developed noninvasive 
method to study the bone density and structure in vivo. QUS 
parameters (speed of sound [SOS], broadband ultrasound 
attenuation [BUA], and stiffness index [SI]) can predict the 
risk of development of hip, wrist, and total nonvertebral 
fractures over a period of up to 10 years.4 It may be possible 
to better account for structural changes of the bone by means 
of QUS than by the traditional DXA method.5 Gonnelli et al6 
reported that ALN treatment increased the QUS parameters 
at the calcaneus in postmenopausal women with osteoporosis 
(at 1 year, SOS: 0.4%, BUA: 1.1%, and SI: 3.2%; at 4 years, 
SOS: 1.2%, BUA: 1.9%, and SI: 9.0%). Thus, QUS of the 
calcaneus can be a useful tool for monitoring the response 
to ALN treatment.
RCTs in postmenopausal women with osteoporosis in 
Japan have indicated that short-term (1–3 years) ALN treat-
ment suppresses bone turnover, increases BMD, and reduces 
the incidence of vertebral fractures.7–10 However, the effect 
of ALN treatment on the QUS parameters remains to be 
established in Japanese patients. The SOS at the calcaneus 
can be measured using a QUS device (CM-200; Elk Corp., 
Osaka, Japan). The authors hypothesized that ALN treatment 
would produce an increase of the SOS at the calcaneus in 
Japanese patients similar to the increase produced in Cauca-
sian patients. The aim of the present clinical practice-based 
observational study was to examine the influence of 1 year’s 
ALN treatment on the SOS and on bone turnover markers in 
postmenopausal Japanese women with osteoporosis.
Material and methods
Subjects
Forty-five postmenopausal Japanese women with osteoporo-
sis who had been treated with ALN (35 mg weekly) for more 
than 1 year at the outpatient clinic of Hiyoshi Medical Clinic 
(Kanagawa, Japan) were identified during the 6-month period 
between October 1, 2011, and March 31, 2012, and were 
retrospectively analyzed. The 35 mg weekly dose indicated 
is the dose used in Japan for the treatment of osteoporosis in 
postmenopausal women and has been recognized as being 
safe and effective.7–10 All of women identified had been estro-
gen or bisphosphonate naïve. They had started ALN treat-
ment during the 18-month period between October 1, 2009, 
and March 31, 2011, and had been continuing the treatment 
for more than 1 year at the authors’ outpatient clinic. The 
inclusion criterion prior to ALN treatment was postmeno-
pausal osteoporosis according to the Japanese   diagnostic 
criteria11,12 – namely, patients with (1) a BMD , 70% of 
the young adult mean (YAM) or “present” osteopenia on 
X-ray images of the spine or (2) a BMD of 70%–80% of 
the YAM or “possible” osteopenia on X-ray images of the 
spine along with a history of osteoporotic fractures. Because 
spine DXA is considered as a useful monitoring method for 
osteoporosis in Japanese women, and because QUS appears 
to be less useful,13 the diagnosis of osteoporosis was under-
taken using both the SOS (,70% of the YAM or 70%–80% 
of the YAM along with a history of osteoporotic fractures) 
and the X-ray findings of the spine (“present” osteopenia or 
“possible” osteopenia along with a history of osteoporotic 
fractures). The exclusion criterion was a history of reflux 
esophagitis, gastric or duodenal ulcer, gastrectomy, renal 
failure, or bone diseases, including cancer-induced bone 
loss because of aromatase inhibitors, primary hyperpara-
thyroidism, hyperthyroidism, Cushing’s syndrome, multiple 
myeloma, Paget’s disease of the bone, rheumatoid arthritis, 
and osteogenesis imperfecta. None of the patients received 
elementary calcium or natural vitamin D supplementation, 
although they were instructed with the aid of brochures to 
achieve daily intakes of 800 mg of calcium and 800 IU of 
vitamin D through food consumption.
The assessment performed prior to the start of the ALN 
treatment included a medical history, physical examination, 
plain radiography of the thoracic and lumbar spine, measure-
ment of the SOS of the calcaneus, and blood and urinary 
biochemical tests – including serum calcium, phosphorus, 
and alkaline phosphatase (ALP) – and urinary cross-linked 
N-terminal telopeptides of type I collagen (NTX). The uri-
nary NTX levels were measured at 3 months after the start of 
treatment. The serum levels of calcium, phosphorus, and ALP 
and the SOS of the calcaneus were measured every 6 months 
after the start of treatment. Plain X-rays of the thoracic and 
lumbar spine were taken after 1 year of treatment. The out-
come of ALN treatment for 1 year was evaluated.
Assessment of morphometric  
vertebral fractures
Plain lateral X-ray films of the thoracic and lumbar spine 
were obtained at the baseline to detect evidence of morpho-
metric vertebral fractures. According to the Japanese criteria, 
a   vertebral fracture is defined according to the vertebral height 
on lateral X-ray films.11,12 Briefly, the vertebral height is mea-
sured at the anterior (A), central (C), and posterior (P) parts 
of the vertebral body, and the presence of a vertebral fracture 
is confirmed when (1) a reduction in the vertebral height of 
more than 20% (A, C, and P) as compared with the height of 
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the adjacent vertebrae is observed, (2) the C/A or C/P ratio 
is ,0.8, or (3) the A/P ratio was ,0.75. The assessment for 
vertebral fractures was performed at the T4–L4 level.
Assessment of clinical vertebral  
and nonvertebral fractures
Low-trauma osteoporotic clinical fractures were assessed. 
Clinical vertebral fractures were determined based on the clin-
ical symptoms and findings of radiographies or magnetic reso-
nance images of the lumbar and thoracic spine.   Nonvertebral 
fractures in terms of major osteoporotic fractures at the distal 
radius, proximal humerus, and hip were determined based on 
the clinical symptoms and radiographic findings of the wrist, 
shoulder, and hip joints, respectively.
Measurement of serum calcium, 
phosphorus, ALP, and urinary NTX
Serum and urine samples obtained from each patient were 
sent to Kotobiken Medical Laboratories, Inc (Yokohama, 
Kanagawa, Japan) for biochemical analyses. The serum 
calcium and phosphorus levels were measured using the stan-
dard laboratory techniques. The serum ALP levels were mea-
sured using the Japan Society of Clinical Chemistry reference 
method. The coefficient of variation (CV = 100 ×   standard 
deviation/mean) of two consecutive measurements within 
a day was ,1.15% among 20 persons. The CV of two 
measurements at the same time point on 2 consecutive days 
was ,4.08% among six persons. The urinary NTX levels 
were measured using an enzyme-linked immunosorbent 
assay. The CV of two consecutive measurements within a 
day was ,7.4% among ten persons. The CV of two mea-
surements at the same time point on 2 consecutive days 
was ,15.0% among 24 persons.
Measurement of SOS of the calcaneus
The SOS of the left calcaneus was measured using a QUS 
device (CM-200; Elk Corporation, Osaka, Japan). Both the 
reliability and the reproducibility of this QUS device have 
been reported as follows: the CV using the phantom tech-
nique was 0.15%, and that in vivo was 0.27%.14
Statistical analysis
The data are expressed in the tables and figures as mean 
plus or minus standard deviation. A one-way analysis of 
variance (ANOVA) with repeated measurements was used 
to determine the significance of the longitudinal changes 
in the SOS and biochemical markers. A single regression 
analysis was used to examine correlations between change 
in the urinary NTX at 3 months and changes in the SOS at 6 
and 12 months. All the statistical analyses were performed 
using statistical software (StatView-J5.0 for Windows; SAS 
Institute Inc, Cary, NC). A significance level of P , 0.05 
was used for all the comparisons.
Results
Characteristics of study subjects  
at start of treatment
Table 1 shows the anthropometric characteristics of the 
study subjects at the start of the ALN treatment. The mean 
age of the subjects was 69.0 years (range, 47–92 years). 
Table 2 shows the SOS and biochemical markers at the start 
of ALN treatment. The mean SOS was 1465 m/s, which cor-
responds to 64.1% of the YAM. The mean serum calcium, 
phosphorus, and ALP levels were 9.2 mg/dL, 3.4 mg/dL, and 
259 IU/L, respectively, all being within the respective normal 
ranges (8.4–10.2 mg/dL, 2.5–4.5 mg/dL, and 100–340 IU/L, 
respectively). However, the mean urinary NTX level was 
61.7 nmol bone collagen equivalent (BCE)/mmol creatinine 
(Cr), which was higher than the normal range for Japanese 
women (9.3–54.3 nM BCE/mM Cr),15 indicating a high bone 
turnover, characteristic of osteoporosis.
Changes in SOS of the calcaneus
Figure 1 shows the changes in the SOS of the calcaneus. 
A one-way ANOVA with repeated measurements showed 
a significant longitudinal increase in the SOS for 1 year 
(P , 0.0001). The mean rates of change in the SOS after 6 
and 12 months of treatment were both 0.6% (Table 3).
Changes in biochemical markers
Figure 2 shows the changes in the biochemical markers. 
The mean urinary NTX levels decreased to the normal 
range for Japanese women (9.3–54.3 nmol BCE/mmol 
Cr)15 after 3 months of treatment, and the mean serum 
ALP levels decreased and remained within the normal 
range (135–340 IU/L) during the 1-year treatment period. 
A one-way ANOVA with repeated measurements showed 
Table  1  Baseline  anthropometric  characteristics  of  study 
subjects
Anthropometric characteristic Mean ± SD Range
Age (years) 69.0 ± 9.1 47–92
Height (m) 1.54 ± 0.06 1.41–1.70
Body weight (kg) 52.5 ± 8.0 35–80
Body mass index (kg/m2) 22.0 ± 3.3 15.8–35.1
Abbreviation: SD, standard deviation.
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  significant longitudinal decreases in the serum ALP and 
urinary NTX levels (both P , 0.0001). No significant lon-
gitudinal changes in the serum calcium or phosphorus levels 
were observed. The mean rate of change of the urinary NTX 
level after 3 months of treatment was −44.9% (Table 3). 
The mean rates of change in the serum ALP levels after 
6 and 12 months of treatment were −19.7% and −22.2%, 
respectively (Table 3).
Correlations between changes  
in urinary NTX and changes  
in SOS of the calcaneus
A single regression analysis showed that the percent decrease 
in the urinary NTX at 3 months was significantly correlated 
with the percentage increase in the SOS only at 6 months 
(correlation coefficient, 0.299; P , 0.05).
Incident fractures
During the 1-year treatment period, one patient experienced a 
proximal humerus fracture. None of the other patients expe-
rienced morphometric or clinical vertebral fractures.
Side effects
One patient experienced stomach pain and one patient com-
plained of thirst after the start of ALN treatment, but these 
symptoms were transient. Three patients underwent a tooth 
extraction during the 1-year treatment period with ALN. No 
serious adverse events, including osteonecrosis of the jaw, 
femoral diaphysis atypical fractures, or atrial fibrillation,16–18 
were observed.
Discussion
The present study confirmed that ALN treatment decreased 
the urinary NTX and serum ALP levels (−44.9% at 3 months 
and −22.2% at 12 months, respectively), producing a modest 
but significant increase in the SOS of the calcaneus (0.6% at 
both 6 and 12 months) in postmenopausal Japanese women 
with osteoporosis. The discussion points to be focused on 
were (1) whether the decreases in the bone turnover markers 
would be similar to those reported from the authors’ previous 
studies, (2) whether the increase in the SOS of the calcaneus 
would be significant and greater than the range of reproduc-
ibility, and (3) whether the early changes in the urinary NTX 
might predict later changes in the SOS of the calcaneus.
The urinary NTX levels were measured at 3 months after 
the start of the ALN treatment. Measuring the urinary NTX 
levels at this time after the start of ALN treatment provides 
important information and is sufficient to monitor the effects 
of treatment of osteoporosis.19 The authors’ previous clini-
cal practice-based observational studies showed that ALN 
treatment decreased the urinary NTX (by about −45% at 
3 months) and serum ALP (by about −21.0% at 1 year) in 
postmenopausal Japanese women with osteoporosis,20–23 
which is consistent with the results of previous RCTs.8,10 
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Figure 1 Changes in speed of sound (SOS).
Notes:  Data  are  expressed  as  mean  plus  or  minus  standard  deviation;  the 
longitudinal changes in the SOS were analyzed using a one-way analysis of variance 
with repeated measurements; the longitudinal changes in the SOS were statistically 
significant (P , 0.0001).
Table  3  Percentage  changes  in  speed  of  sound  (SOS)  and 
biochemical markers
Variable 3 months 6 months 12 months
SOS 0.6 ± 1.0 0.6 ± 1.0
Calcium −1.2 ± 4.1 −0.7 ± 5.1
Phosphorus −1.2 ± 13.8 2.6 ± 13.6
ALP −19.7 ± 18.2 −22.2 ± 20.2
Urinary NTX −44.9 ± 27.1
Note: Data are expressed as mean plus or minus standard deviation.
Abbreviations:  ALP,  alkaline  phosphatase;  NTX,  cross-linked  N-terminal 
telopeptides of type I collagen.
Table  2  Baseline  speed  of  sound  (SOS)  and  biochemical 
markers
Variable Mean ± SD Range
SOS (m/s) 1465 ± 14 1433–1498
%YAM in SOS (%) 64.1 ± 6.4 49–79
Calcium (mg/dL) 9.2 ± 0.3 8.6–10.0
Phosphorus (mg/dL) 3.4 ± 0.5 1.6–4.1
ALP (IU/L) 259 ± 72 132–439
Urinary NTX (nM BCE/mM Cr) 61.7 ± 25.8 19.9–126.3
Notes: Normal ranges of serum calcium, phosphorus, and ALP were 8.4–10.2 mg/dL, 
2.5–4.5 mg/dL, and 100–340 IU/L, respectively; standard range of urinary NTX was 
9.3–54.3 nM BCE/mM Cr, and cutoff values of bone loss and vertebral fracture risk 
were 35.3 and 54.3 nM BCE/mM Cr, respectively.
Abbreviations: %YAM, percentage of young adult mean; ALP, alkaline phosphatase; 
BCE,  bone  collagen  equivalent;  Cr,  creatinine;  NTX,  cross-linked  N-terminal 
telopeptides of type I collagen; SD, standard deviation.
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The reductions in the urinary NTX and serum ALP levels 
in the present study were comparable with those reported 
from previous studies. Clinical practice-based observational 
studies confirmed that ALN treatment for 1 year success-
fully suppressed bone turnover in postmenopausal Japanese 
women with osteoporosis.
The mean age of the study subjects at the start of the ALN 
treatment was 69.0 years. The reference values of the SOS 
of the calcaneus in healthy Japanese women are 1487 m/s 
for those aged 65–69 years and 1481 m/s for those aged 
70–74 years.24 ALN treatment for 1 year increased the SOS 
of the calcaneus (1465 m/s at baseline, 1474 m/s at 6 months, 
and 1475 m/s at 12 months). Therefore, it was considered 
that ALN treatment might be useful for   increasing the SOS 
of the calcaneus in postmenopausal Japanese women with 
  osteoporosis. The rates of increase of the SOS were 0.6% at 
both 6 and 12 months, similar to the rates of increase reported 
in postmenopausal Caucasian women with osteoporosis 
(0.4% at 1 year).6 Because the CV in vivo for the measure-
ment of the SOS of the calcaneus was 0.27%,14 the increase 
in the SOS of the calcaneus in the present study might be 
clinically significant.
The percentage decrease in the urinary NTX at 3 months 
was significantly correlated with the percentage increase in 
the SOS only at 6 months (correlation coefficient, 0.299). 
ALN treatment rapidly decreased the urinary NTX level 
up to 3 months, with the values maintained thereafter.10 
The early changes in the urinary NTX may be the key in 
patients treated with ALN. The results of the present study 
suggest that early changes in the urinary NTX after the start 
of ALN treatment may be predictive of an increase in the 
SOS of the calcaneus. However, the percentage decrease in 
the urinary NTX at 3 months was not significantly correlated 
with the percentage increase in the SOS at 12 months, prob-
ably because the SOS of the calcaneus may also have been 
significantly affected by various other factors, including 
lifestyle and seasonal variations, during the 1-year treatment 
period with ALN.25–27
The authors’ previous study found that early changes in 
the urinary NTX were correlated with the 1-year response to 
the lumbar spine BMD to ALN treatment in postmenopausal 
Japanese women with osteoporosis.19 Conversely, Kaji et al28 
reported that BMD increase at the lumbar spine after bis-
phosphonate treatment was not related to any pretreatment 
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Figure 2 Changes in biochemical markers.
Notes: Data are expressed as mean plus or minus standard deviation; the longitudinal changes in biochemical markers were analyzed using a one-way analysis of variance 
with repeated measurements; the longitudinal changes in the serum ALP and urinary NTX were statistically significant (both P , 0.0001).
Abbreviations: ALP, alkaline phosphatase; BCE, bone collagen equivalent; Cr, creatinine; NS, not significant; NTX, cross-linked N-terminal telopeptides of type I collagen.
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parameters – including body size, body composition, and 
bone/mineral metabolism – in postmenopausal Japanese 
women with osteoporosis. Subsequently, the correlation 
between decreases in bone turnover markers and increases 
in bone mass parameters after ALN treatment remains con-
troversial. Thus, further studies conducted on a large number 
of Japanese patients are needed to address this issue.
A 3-year RCT in postmenopausal Japanese women with 
osteoporosis showed that the incidence of morphometric 
vertebral fractures was 7.8% for the ALN group without 
patients receiving elementary calcium or natural vitamin 
D supplementation.8 However, in the present study none of 
the subjects experienced morphometric vertebral fractures, 
despite comparable changes in the bone turnover markers and 
SOS after 1-year ALN treatment.6,8,10 The lower incidence of 
morphometric vertebral fractures in the present study may be 
attributable to a lower proportion of frail patients with a higher 
risk of incident fractures at baseline, since osteoporosis was 
not diagnosed precisely using the BMD measured by DXA.
There are notable limitations of the present study. Impor-
tantly, the statistical quality of the present analyses may be 
relatively poor, because of the small sample size, the absence 
of a statistical power for the fracture incidence, and the ret-
rospective nature of the analyses. Further studies are needed 
to reconfirm the authors’ results.
Conclusion
The present study confirmed that ALN treatment suppresses 
bone turnover, producing a clinically significant increase in 
the SOS of the calcaneus in postmenopausal Japanese women 
with osteoporosis.
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